Background. Ombitasvir/paritaprevir/ritonavir with dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV) is approved for hepatitis C virus (HCV) genotype 1 (GT1) treatment in HIV-1 coinfected patients. In healthy controls, coadministration of OBV/PTV/r + DSV + darunavir (DRV) lowered DRV trough concentration (C trough ) levels. To assess the clinical significance of this change, TURQUOISE-I, Part 1b, evaluated the efficacy and safety of OBV/PTV/r + DSV + RBV in coinfected patients on stable, DRVcontaining antiretroviral therapy (ART).
The three DAA agents ombitasvir, paritaprevir (identified by AbbVie and Enanta, and administered with the pharmacoenhancer ritonavir), and dasabuvir comprise the 3D regimen OBV/PTV/r + DSV. Ombitasvir is a potent NS5A inhibitor that is coformulated with PTV, an NS3/4A protease inhibitor; DSV is an NS5B ribonucleic acid (RNA) polymerase inhibitor. The 3D regimen + RBV is approved in the United States and the European Union for treatment of HCV genotype 1 (GT1) infection in HIV-1 coinfected patients [7] [8] [9] . The approved indication was based on Part 1a SVR12 interim data of the TURQUOISE-I study, in which coinfected patients on a stable atazanavir (ATV)-or raltegravir (RAL)-containing antiretroviral therapy (ART) achieved SVR12 rates of 94% and 91% following 12 or 24 weeks of treatment, respectively [10] .
The antiretroviral darunavir (DRV) is a preferred and widely used protease inhibitor in HIV-1 treatment-naive and experienced patients [11] [12] [13] . A recent drug interaction study in healthy volunteers showed that coadministration of the OBV/ PTV/r + DSV regimen with DRV did not significantly change DAA exposures; however, DRV trough concentration (C trough ) levels were 48% and 43% lower with once and twice daily (QD and BID) DRV administration, respectively [14] . Here, we examine the efficacy and safety of OBV/PTV/r + DSV with RBV in patients with HCV GT1/HIV-1 coinfection on a stable, DRVcontaining ART regimen.
METHODS

Overall Study Design
TURQUOISE-I (NCT01939197) is a Phase II/III, multipart, open-label study with the primary objective of evaluating the safety and efficacy (defined as the percentage of patients achieving SVR12) of OBV/PTV/r ± DSV ± ribavirin (RBV) in HCV/ HIV-1 coinfected patients. Part 1a investigated a 12-versus 24-week treatment duration in coinfected patients on ATV-or RAL-containing ART [10] .
Part 1b of TURQUOISE-I is a Phase II study that took place at US sites only, and evaluated the safety and efficacy of OBV/ PTV/r + DSV + RBV for 12 weeks in a small group of HCV GT1/HIV-1 coinfected patients on stable, once-daily versus twice-daily DRV-containing HIV-1 ART before evaluating this regimen in a larger, Phase III study (Part 2). At the time of enrollment, OBV/PTV/r + DSV + RBV was the approved regimen for treatment of GT1b patients; however, it should be noted that the current label recommendation for all GT1b patients with or without cirrhosis is OBV/PTV/r + DSV without RBV.
As a secondary variable in Part 1b only, the pharmacokinetics of once-or twice-daily DRV coadministered with OBV/ PTV/r + DSV + RBV were also evaluated. Patients were randomized in a 1:1 ratio to maintain 800 mg DRV once daily (QD) or switch to 600 mg DRV twice daily (BID) for a minimum of 14 days prior to beginning treatment with the HCV regimen. Patients in the DRV QD arm stopped the ritonavir component of their HIV regimen upon initiating treatment with OBV/PTV/r + DSV + RBV. Patients randomized to switch to DRV BID stopped the morning ritonavir component of their HIV regimen upon initiating OBV/PTV/r + DSV + RBV treatment, but continued the evening dose of ritonavir. For 12 weeks, patients received OBV/PTV/r 25/150/100 mg QD and DSV 250 mg BID with weight-based RBV (1000 or 1200 mg daily, divided in 2 doses based on body weight <75 kg or ≥75 kg, respectively).
All patients provided written informed consent, and all studies were conducted in accordance with International Conference on Harmonization guidelines, other guidelines governing clinical study conduct, applicable regulations, and ethical principles outlined in the Declaration of Helsinki.
Patients
Eligible patients were between the ages of 18 and 70 at the time of screening, with chronic HCV GT1 infection and HCV RNA >10 000 IU/mL. Patients could be either HCV treatment-naive or peg-interferon/RBV treatment-experienced; if treatment-experienced, patients must be documented as null responders, partial responders, or relapsers. At the time of screening, patients also had to have a positive test result for anti HIV antibody, with plasma HIV-1 RNA <40 copies/mL and CD4 + lymphocyte count ≥200 cells/µL or ≥14%, and on a stable, once-daily regimen of DRV in combination with tenofovir disoproxil fumarate (TDF) plus either emtricitabine (FTC) or lamivudine (3TC) for at least 8 weeks prior to screening. Patients were excluded if they had prior HCV DAA experience, clinical evidence of liver decompensation, serum albumin <2.8 g/dL, platelets <60 × 10 9 /L, or chronic hepatitis B infection. HIV-1-related reasons for exclusion included past evidence of DRV resistance-associated mutations (RAMs), treatment for an AIDS-associated opportunistic infection within 12 months of screening, or HIV-2 infection. Randomized patients were stratified by prior HIV treatment history and previous HIV-1 protease inhibitor (PI) treatment-experience.
Study Endpoints, Assessments, and Statistical Analyses
Demographics, safety, and efficacy analyses were performed on the Part 1b intent-to-treat (ITT) population, defined as all patients who received at least 1 dose of study drugs. The primary variable used to assess efficacy was achievement of sustained virologic response (SVR; HCV RNA <25 IU/mL) at post-treatment week 12 (SVR12), using the Roche COBAS AmpliPrep/ COBAS TaqMan HCV Quantitative Test (v2.0). The number and percentage of subjects achieving SVR12 overall and within each treatment arm was calculated along with the 2-sided 95% Wilson score confidence intervals. The primary endpoint was the comparison of SVR12 rates between arms using the Fisher exact test.
Secondary endpoints included the number and percentage of patients with (1) on-treatment HCV virologic failure, (2) post-treatment relapse, (3) maintenance of plasma HIV-I RNA suppression at the end of treatment and at SVR12, and (4) SVR12 in the DRV QD arm compared to the DRV BID arm, and the combined SVR12 rate across arms. Plasma and serum samples were collected at day 1, week 1, week 2, and every 2 weeks thereafter through the end of the treatment period. Maintenance of plasma HIV-1 RNA suppression was examined using the US Food and Drug Administration Snapshot algorithm, and determined using the Plasma HIV-1 RNA Assay (Abbott Realtime), which has a lower limit of quantification of 40 copies/mL.
Nine plasma samples for intensive pharmacokinetic analyses of DRV were collected prior to (day -1) and following initiation (week 4) of treatment with OBV/PTV/r + DSV plus RBV. DRV maximum observed plasma concentration (C max ), trough plasma concentration (C 24 for DRV QD, and C 12 for DRV BID), and the area under the plasma concentration-time curve during the dosing interval (AUC 24 for DRV QD, and AUC 12 for DRV BID) were determined using noncompartmental analyses (SAS Version 9.2; SAS Institute, Inc, Cary, NC). Sparse pharmacokinetic plasma samples were collected at day 1 and weeks 1, 2, 6, 8, 10, and 12. Samples collected 20 to 26 hours postdose for DRV QD and 10-14 hours postdose for DRV BID were considered as the trough concentration (C trough ) when assessing DRV exposures relative to plasma HIV RNA. Plasma concentrations of DRV were determined using validated liquid chromatography methods with tandem mass spectrometry detection (PPD Laboratories, Middleton, WI). Repeated-measures analyses for log-transformed C max , AUC 12 or 24 , and C 12 or 24 values were performed to obtain the least squares means ratios and 90% confidence intervals (CIs), comparing exposures for DRV alone versus after coadministration with OBV/PTV/r + DSV plus RBV.
Adverse events (AEs) and laboratory and vital sign parameters were assessed at each study visit in all patients receiving at least 1 dose of study drugs. AEs collected from the time of first dose of study drug to 30 days after last dose of study drug were designated treatment-emergent AEs (TEAEs). The severity and causality (as related to the study drugs) of AEs was assessed by the investigator. Clinical laboratory testing was performed throughout the study period until SVR12.
RESULTS
Patients
In total, 121 patients were screened: 87 patients failed to meet the inclusion or exclusion criteria, 6 patients withdrew consent, and 1 was lost to follow up. Twenty-two patients (73% of target) were enrolled in the study between 7 November 2014 and 7 July 2015. Ten patients were randomized to receive OBV/ PTV/r + DSV + RBV and DRV QD, and 12 were randomized to receive OBV/PTV/r + DSV + RBV and DRV BID. Baseline demographics and clinical characteristics are presented in Table  1 . The majority of patients (15/22, 68%) had HCV GT1a infection. Forty-one percent of patients identified as black race and 14% had compensated cirrhosis. Thirty-two percent of patients had DRV as their first protease inhibitor.
Efficacy and Plasma HIV-I RNA Suppression
Sustained virologic response at post-treatment week 4 (SVR4) and SVR12 were achieved by 100% (22/22) of patients ( Figure 1) . As of post-treatment week 24, no relapses have been reported. There was no difference in SVR between patients taking QD versus BID DRV.
The majority of patients maintained plasma HIV-1 RNA suppression (Figure 2 ). Transient HIV viremia occurred in 22% (5/22) of patients during the treatment period. Two patients taking QD DRV and 3 patients taking BID DRV experienced "blips" of intermittent viremia (plasma HIV-1 RNA ≥40 and <200 copies/ mL) during treatment. The highest HIV-1 RNA recorded during the treatment period was 79 copies/mL. This patient was in the DRV QD treatment arm, and had HIV-1 plasma RNA of 42 copies/mL at baseline. HIV-1 RNA of 42, 49, 52, and 79 copies/mL were recorded at treatment weeks 4, 6, 8, and 10, respectively; however, no HIV-1 RNA was detected at treatment week 12 or any week thereafter through post-treatment week12. All but 1 patient had HIV-1 RNA suppression <40 copies/mL at end of treatment. This patient was in the BID treatment arm and had HIV-1 RNA of 64 copies/mL at treatment week 12 only; HIV-1 RNA suppression was maintained at all prior and follow-up visits. Two patients experienced blips during the post-treatment period only (day 85, and days 29 and 45 following treatment, respectively). 
Darunavir Pharmacokinetics and Exposures Relative to Plasma HIV RNA
Coadministration of DRV and OBV/PTV/r + DSV + RBV had minimal impact on DRV C max and AUC 12 or 24 . DRV C trough were 36% lower with DRV QD and 27% lower with DRV BID (Table 2) . DRV C trough levels are plotted in Figure 3A for the QD arm and Figure 3B for the BID arm. In both arms, all DRV C trough levels associated with an HIV RNA >40 copies/mL were above the DRV median effective concentration required to induce a 50% effect (EC 50 ; adjusted for protein binding) of 550 ng/mL for resistant virus [15] .
Safety and Tolerability
Twenty patients (91%) experienced AEs; the majority of these were mild in severity (Table 3 ). The most common AEs (>15%) were fatigue, a decrease in hemoglobin, irritability, and nausea. There was 1 serious AE: 1 patient in the DRV BID arm experienced colitis and dehydration on day 38 of treatment (the AE was deemed not related to the study drug). There were no treatment interruptions or discontinuations due to AEs. Nine patients had RBV dose modifications due to AEs; of these, 5 were due to decreased hemoglobin levels, 3 were due to anemia, and 1 was due to fatigue. No Grade 3 or higher on-treatment laboratory abnormalities were reported.
DISCUSSION
In this study investigating the safety and efficacy of OBV/PTV/r + DSV with RBV in patients with chronic HCV GT1 infection and HIV-1 coinfection, 100% of patients on stable, once-daily DRV achieved SVR12 regardless of maintaining once-daily or switching to twice-daily DRV administration. Treatment was well tolerated, with the majority of AEs reported as mild in severity. There were no treatment discontinuations due to TEAEs, and the overall safety profile is consistent with what has been previously observed in patients receiving OBV/PTV/r + DSV with RBV [16] [17] [18] .
Episodes of intermittent HIV-1 viremia were infrequent and similar to the rate observed in larger cohort studies [19] . Plasma HIV-1 RNA was monitored at least every 2 weeks in this study; as this is greater than the monitoring frequency for ambulatory HIV-infected patients on stable ART, a detection bias for the rate of low-level HIV viremia may have existed. Two patients in the DRV QD and 3 patients in the DRV BID treatment arms experienced viral blips of HIV-1 plasma RNA between 40-200 copies/mL during treatment, and 2 patients in the BID arm experienced blips during the post-treatment period only. None of these blips were associated with a DRV plasma concentration <550 ng/mL, the DRV EC 50 for resistant virus. Recent data support our finding that virologic blips have minimal impact on maintenance of HIV-1 viral suppression. In a large, observational cohort in which 21% of patients had HIV-1/HCV GT1 coinfection, Grennan and colleagues [19] found that blips >500 copies/ mL were associated with virologic rebound, whereas blips 50-499 copies/mL were not. Although for the purposes of our study, a "blip" was defined as HIV-1 RNA ≥40 and <200 copies/mL, 2 of 5 patients would not have met the more frequently used criteria for determining blips of intermittent viremia, which is HIV-1 RNA >50 copies/mL [20, 21] . It is likely that the blips recorded, particularly those <55 copies/ mL as found in the majority of patients, did not represent clinically significant viremia, nor are they likely to be indicative of resistance mutation development. As the sensitivity of HIV-1 RNA quantification assays improves, so does the frequency of reported low-level intermittent viremia; notably, values that are close to the lower cut-off may be due to residual viremia with fluctuations around a mean value of HIV RNA 50 copies/mL or laboratory assay artifacts [22] .
Intensive pharmacokinetic evaluations were performed to determine whether OBV/PTV/r + DSV plus RBV significantly alters DRV pharmacokinetics. The magnitude of the changes in DRV C trough in the QD and BID DRV dosing regimens were smaller than the changes observed in healthy volunteers (decrease 37% vs 48% with DRV QD, and 27% vs 43% with DRV BID) and not expected to be clinically significant. Indeed, previous studies suggest that exposures may be lowered up to 50% without negatively impacting efficacy [23, 24] . Consistent with this, no relationship between reductions in DRV C trough levels and intermittent viremia was observed. These results suggest that HIV coinfected patients on a stable regimen containing DRV/r 800 mg/100 mg QD could be treated with OBV/PTV/r + DSV plus RBV for their HCV without an increased risk of HIV virologic failure. These results, however, cannot be extrapolated to HIV treatment-experienced adult patients with 1 or more DRV RAMs who are being treated with DRV/ritonavir 600/100 mg BID. Though further studies are needed, these findings are important because DRV is widely used in ART regimens, and patients on DRV-containing ART often have limited antiretroviral switch options to accommodate HCV therapy. TURQUOISE-I, Part 2 is a global, multicenter Phase III trial conducted in 233 patients with or without cirrhosis that evaluates the two DAA regimen OBV/PTV/r plus RBV for treatment of HCV genotype 4/HIV-1 coinfection and OBV/ PTV/r + DSV with or without RBV for treatment of GT1a/ HIV-1 and GT1b/HIV-1 coinfection, respectively. The results presented herein provide clinicians with evidence of a safe and effective HCV treatment option for HIV treatment-naive HIV-1/HCV GT1 coinfected patients without DRV resistance mutations that are currently using QD DRV-containing ART. 
Notes
